Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Firvanq for C.diff-associated Diarrhea

CutisPharma news release; 2018 Jan 29

The FDA has approved Firvanq (vancomycin hydrochloride) oral liquid therapy to treat Clostridium difficile-associated diarrhea and enterocolitis resulting from Staphylococcus aureus.

Indications: Firvanq (vancomycin hydrochloride) for oral solution, is approved for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

Dosage/administration: Firvanq will be available in 25 mg/mL and 50 mg/mL strengths in convenient 150 mL and 300 mL sizes. It is designed to be easy to use and has the potential to be a cost-effective alternative to existing vancomycin therapies.

Citation:

CutisPharma announces FDA approval of FIRVANQ. [news release]. Wilmington, MA: CutisPharma; January 29, 2018. http://cutispharma.com/cutispharma-announces-fda-approval-firvanq/. Accessed January 30, 2018.

This Week's Must Reads

Difficult-to-Treat Resistance in GNBSIs, Clin Infect Dis; ePub 2018 Jul 23; Kadri, et al

Missed Opportunities for HIV Testing, Open Forum Infect Dis; ePub 2018 Jul 19; Kapadia, et al

Bacterial STI Screening Rates Among MSM, Sex Transm Dis; ePub 2018 Jul 24; Jenness, et al

Patient Engagement in HIV Care, AIDS; ePub 2018 Jul 12; Lee, Wu, et al

IDSA/ASM Lab Guide for Diagnosis of IDs, Clin Infect Dis; ePub 2018 Jun 28; Miller, et al

Must Reads in Antimicrobial-resistant infections

Difficult-to-Treat Resistance in GNBSIs, Clin Infect Dis; ePub 2018 Jul 23; Kadri, et al

Antimicrobial Therapy for Acute Otitis Media, J Infect Dis; ePub 2018 Jun 5; Lewnard, et al

Antimicrobial Prescribing After CDI Diagnosis, Am J Infect Contr; ePub 2018 May 17; Watson, et al

Costs of MRSA vs MSSA Infections in the US, Open Forum Infect Dis; ePub 2018 May 12; Klein, et al

Antimicrobial Stewardship in the ED to Improve UTI, Open Forum Infect Dis; ePub 2018 May 2; Jorgensen, et al